BioSpace News Archive

Inventiva announced that it has completed sales of 2,083,334 of American Depositary Shares pursuant to the Company’s ATM program established on August 2, 2021, through Jefferies LLC, acting as sales agent.

Diadem srl announced release of a new publication, Post-Translational Modifications of the p53 Protein and the Impact in Alzheimer’s Disease, that reviews how post-translational modifications of the p53 protein may impact the development of Alzheimer’s disease.

exocad GmbH, an Align Technology, Inc. company and a leading dental CAD software provider, detailed the company’s achievements over the past year and recent productivity-boosting software innovations at its International Dental Show press event.

Tubulis announced the formation of a Scientific Advisory Board with the appointment of international industry experts in the development of antibody drug conjugates and in-depth knowledge in the therapeutic areas of oncology and hematology.

Greenwich LifeSciences, Inc. announced its participation in the 2021 Cantor Virtual Global Healthcare Conference from September 27-30, 2021.

MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that it has received FDA 510 clearance for the detection of wounds containing clinically significant levels of Pseudomonas aeruginosa for the previously cleared MolecuLight i:X imaging device.

Draupnir Bio announces the establishment of its scientific advisory board comprising global leaders in carbohydrate chemistry, the regulation and genetics of cholesterol metabolism, and in drug development for the treatment of cardiovascular disease.

Microbix Biosystems Inc., a life sciences innovator and exporter, announces that it will be presenting to investors at the Muskoka Capital Conference, organized by Capital Event Management Ltd. and being hosted at the JW Marriott Rosseau Muskoka, in Minett, ON, September 24-26, 2021.

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, will host a virtual R&D Day beginning at 12:00 p.m., Eastern Time.

ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced that Adam Grossman, President and Chief Executive Officer, will participate in a virtual fireside chat at the Cantor Healthcare Conference on September 30, 2021, at 9:20 a.m. ET.